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Neuro-inflammation, one of the pathogenic causes of neurodegenerative diseases,
is regulated through the cholinergic anti-inflammatory pathway via the α7 nicotinic
acetylcholine receptor (α7 nAChR). We previously showed that either bacterial
lipopolysaccharide (LPS) or immunization with the α7(1–208) nAChR fragment
decrease α7 nAChRs density in the mouse brain, exacerbating chronic inflammation,
beta-amyloid accumulation and episodic memory decline, which mimic the early
stages of Alzheimer’s disease (AD). To study the molecular mechanisms underlying
the LPS and antibody effects in the brain, we employed an in vivo model of
acute LPS-induced inflammation and an in vitro model of cultured glioblastoma
U373 cells. Here, we report that LPS challenge decreased the levels of α7 nAChR
RNA and protein and of acetylcholinesterase (AChE) RNA and activity in distinct
mouse brain regions, sensitized brain mitochondria to the apoptogenic effect of
Ca2+ and modified brain microRNA profiles, including the cholinergic-regulatory
CholinomiRs-132/212, in favor of anti-inflammatory and pro-apoptotic ones. Adding
α7(1–208)-specific antibodies to the LPS challenge prevented elevation of both
the anti-inflammatory and pro-apoptotic miRNAs while supporting the resistance
of brain mitochondria to Ca2+ and maintaining α7 nAChR/AChE decreases. In
U373 cells, α7-specific antibodies and LPS both stimulated interleukin-6 production
through the p38/Src-dependent pathway. Our findings demonstrate that acute
LPS-induced inflammation induces the cholinergic anti-inflammatory pathway in the
brain, that α7 nAChR down-regulation limits this pathway, and that α7-specific
antibodies aggravate neuroinflammation by inducing the pro-inflammatory interleukin-6
and dampening anti-inflammatory miRNAs; however, these antibodies may protect
brain mitochondria and decrease the levels of pro-apoptotic miRNAs, preventing
LPS-induced neurodegeneration.
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INTRODUCTION
Neuro-inflammation accompanies and often precedes the
development of neurodegenerative pathologies such as
Parkinson’s and Alzheimer’s diseases (AD; Wee Yong, 2010) and
might be one of the pathogenic factors for neurodegeneration
(Chung et al., 2010; Heppner et al., 2015). However, the
molecular mechanisms linking inflammatory reaction to
degeneration in the brain are poorly understood. One of the
cross-points may include nicotinic acetylcholine receptors of the
α7 subtype (α7 nAChRs), which are involved in both cholinergic
anti-inflammatory and pro-survival intracellular pathways
(Ji et al., 2014; Báez-Pagán et al., 2015; Terrando et al., 2015;
Truong et al., 2015).
A number of studies point out the involvement of α7 nAChRs
in pro-survival cell signaling, engaging the PI3K/Akt signaling
pathway (Parada et al., 2010; Yu et al., 2011; Cucina et al.,
2012; Huang et al., 2012; Cui et al., 2013). Such signaling was
shown to protect cultured brain cells from apoptosis induced
by various apoptogenic agents (Parada et al., 2010). Moreover,
α7 nAChRs were found to regulate mitochondrial permeability
transition pore formation and release of apoptogenic factors like
cytochrome (cyt c) and therefore, to control the mitochondrial-
mediated pathway of apoptosis (Gergalova et al., 2012,
2014).
In addition, α7 nAChR directly interacts with the amyloid-
beta (Aβ) precursor protein (Ikonomovic et al., 2009), which
favors its normal processing by α-secretase (Kim et al., 1997;
Qi et al., 2007) and promotes internalization of processed
Aβ forms (Wang et al., 2000; Parri and Dineley, 2010).
Consequently, the decrease of α7 nAChR density on the plasma
membrane impairs Aβ metabolism and favors accumulation of
extracellular Aβ (1–42) (Gouras et al., 2005; Dziewczapolski et al.,
2009).
Previously, we found that regular injections of bacterial
lipopolysaccharide (LPS) decreased the density of α7 nAChRs
in the brain and brain mitochondria of mice and reduced
nucleated cell numbers in the hippocampus and striatum, while
stimulating astrocytosis, accumulation of Aβ (1–42) peptides
and episodic memory decline—symptoms characteristic of
the early stages of AD (Lykhmus et al., 2015). Antibodies,
generated in vivo by immunization of mice with recombinant
extracellular domain of α7 nAChR subunit, α7(1–208),
facilitated symptoms similar to those induced by LPS but
did not cause degeneration in the brain of mice (Lykhmus
et al., 2015), indicating the involvement of specific regulatory
processes.
Another important regulator of cholinergic signaling is
acetylcholinesterase (AChE), the levels of which decrease during
inflammation, increasing acetylcholine levels and stimulating
the anti-inflammatory pathway (Soreq, 2015). Acetylcholine was
shown to attenuate the release of pro-inflammatory cytokines,
like IL-1 or TNFα, by peritoneal monocytes and macrophages
in response to bacterial endotoxin—LPS through α7 nAChRs
(Borovikova et al., 2000). This phenomenon, first described in
2000 and called ‘‘Cholinergic Anti-Inflammatory Pathway’’, was
further observed in many organs and tissues including the brain
(de Jonge and Ulloa, 2007; Tyagi et al., 2010; Thomsen and
Mikkelsen, 2012; Ji et al., 2014; Báez-Pagán et al., 2015; Egea et al.,
2015; Truong et al., 2015). AChE expression has been shown
to be regulated by microRNAs (miRNAs), small non coding
RNAs suppressors of entire pathways of gene expression (Chen
et al., 2004; Soreq and Wolf, 2011). MiRNA-132 is reported
to increase during inflammation in many tissues (Maharshak
et al., 2013; Shaltiel et al., 2013; Nadorp and Soreq, 2015) and is
validated to target AChE further to potentiate cholinergic anti-
inflammatory pathway (Shaked et al., 2009; Soreq and Wolf,
2011).
The present study was aimed to reveal the molecular
mechanisms underlying the LPS and antibody effects in the
brain, using a model of acute LPS-induced inflammation with or
without α7-specific antibody injections. Specifically, we studied
the involvement of α7 nAChRs in brain inflammation and
mitochondrial apoptosis, measured changes in AChE levels
with inflammation and profiled brain miRNAs under exposure
to LPS, LPS and α7-specific antibody (Ab α7) or nicotine.
Our findings indicate that LPS down-regulates α7 nAChR and
AChE in the brain; exacerbates the mitochondrial pathway of
apoptosis and changes brain miRNAs in favor of pro-apoptotic
and anti-inflammatory ones. Inversely, the antibody supports
the integrity of brain mitochondria and attenuates the LPS-
induced pro-apoptotic miRNAs up-regulation while stimulating
pro-inflammatory signaling and preventing the LPS-induced
elevation of the anti-inflammatory miRNA-132/212 (Shaked
et al., 2009; Shaltiel et al., 2013; Soreq, 2015).
MATERIALS AND METHODS
Animals and Reagents
Female 3 months old C57BL/6J mice were housed in a quiet,
temperature-controlled room (22–23◦C) in the animal
facility of the O.V. Palladin Institute of Biochemistry and
were provided with water and dry food pellets ad libitum.
Mice were sacrificed by cervical dislocation to remove
the brain. All procedures of this study conformed to the
guidelines of the Animal Care and Use Committee of
Palladin Institute and were approved by the IACUC Protocol
1/7–421.
All reagents were of chemical grade and were purchased
from Sigma-Aldrich unless specially indicated. Antibodies
against α7(1–208), α7(179–190), α3(181–192), α4(181–192),
β2(190–200) and β4(190–200) nAChR fragments were obtained
and characterized by us previously (Skok et al., 1999; Koval et al.,
2004; Lykhmus et al., 2011).
Glioblastoma U373 cells (ATCC HTB17–1055) were a kind
gift of Prof. A.V.Ryndich from the Institute of Molecular Biology
and Genetics in Kyiv.
Animal Treatment and Samples
Preparation
Mice were intra-peritoneally injected with LPS (30 µg/mouse
in PBS) on days 0 and 2 (groups 1 and 2). Group 2 mice
were additionally intravenously injected with α7(1–208)-specific
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antibodies (200 µg/per mouse in saline) on days 0, 1 and 2.
Group 3 mice received nicotine in the drinking water (200 µl/l)
for either 3 days or 1 month and the 4th group was intact
(Ctrl).
On the 3rd day of each treatment, mice were sacrificed;
their brains were removed, homogenized and fractionated
into primary pellets (nuclei, cell debris) and mitochondria
(additionally pelleted from the supernatant) by a standard
procedure of differential centrifugation (Gergalova et al.,
2012). To quantify nAChR subunits, both mitochondria and
primary pellets were lysed in detergent-containing buffer.
Live mitochondria were further examined for functional
activities.
In another set of experiments, the brains of similarly
treated mice were divided into two halves (hemispheres) and
each half was dissected into Hippocampus, Striatum/Thalamus,
Cerebellum and Frontal cortex. The one half sections were
homogenized under liquid nitrogen and used for RNA
extraction. Sections of the 2nd half were homogenized; lysed
in detergent-containing buffer (0.01 M Tris-HCl, pH 7.4, 1 M
NaCl, 1 mM EGTA, 1% Triton X-100) for 45 min on ice and
centrifuged at 13,000 rpm. The resulting supernatant was used
for quantifying AChE activity and α7 nAChR protein. Protein
content was measured with the BCA kit (Thermo Scientific,
France).
Cytochrome c (cyt c) Release Assay with
Live Mitochondria
Cyt c release from isolated mitochondria was measured as
described previously (Gergalova et al., 2012). Briefly, purified
mitochondria (120 µg of protein per ml) were incubated with
different doses of CaCl2 with or without the α7 nAChR agonist
PNU282987 (30 nM) for 2 min at room temperature and
were immediately pelleted by centrifugation. The supernatants
were tested for the presence of cyt c by a sandwich ELISA
assay.
Quantifying nAChR Subunits in the Brain or
Mitochondria Preparations
The assay was performed as described Lykhmus et al. (2015).
Briefly, immunoplates (NUNC, MaxiSorp) were coated with
rabbit α7(1–208)-specific antibody (20 µg/ml), blocked with 1%
BSA, and the tested preparations were applied into the wells (1µg
of protein per 0.05 ml per well) for 2 h at 37◦C. The plates were
washed with water and the second biotinylated α3(181–192),
α4(181–192), α7(179–190), β2(190–200) or β4(190–200)-specific
antibody was applied for additional 2 h being revealed
with Streptavidin-peroxidase conjugate and o-phenylendiamine-
containing substrate solution.
RT-PCR for α7, AChE and microRNA
Transcripts
RNA extraction from tissue samples was carried out
using Trizol (Sigma, NY, USA) as described Shaked et al.
(2009). RNA concentration and integrity were determined
spectrophotometrically and by electrophoresis, respectively.
RNA samples (500 ng) were reverse transcribed using the
Quanta cDNA synthesis kit for mRNA and miRNA as per
the manufacturer’s (Quanta Biosciences) protocol. Real-time
RT-PCR was performed using the ABI prism 7900 HT and SYBR
green master mix (Quanta Biosciences). For miRNA transcripts,
PerfeCTa microRNA assay primers (Quanta Biosciences) were
used. Results were normalized to the expression of snoRD47
and actin for miRNA and mRNA respectively. Further all
the results were normalized to respective regional control.
The following primers were used for: AChE-S Forward (F):
CTGAACCTGAAGCCCTTAGAG, Reverse (R): CCGCCTCG
TCCAGAGTAT; nAChR7, F: CACATTCCACACAACGTCTT,
R: AAAAGGGAACCAGCGTACATC; actin F: CCACACCCG
CCACCAGTT, R: TACAGCCCGGGGAGCAT. Fold change
values for both miRNAs and mRNAs were calculated using the
∆∆Ct method.
RNA-seq Library Preparation and
Sequencing
Libraries for next generation sequencing (NGS) were prepared
from whole brain RNA using TruSeq Small RNA Library Prep
Kit as per the manufacturer’s protocol. A total of four libraries
(pooled from four animals of each group) were prepared
from RNA of four groups. Briefly, the total 600 ng of RNA
samples were hybridized with Trueseq Adaptor Mix which
is a set of oligonucleotides with a single-stranded degenerate
sequence at one end and a defined sequence required for
Miseq sequencing at the other end. The Adaptor Mix constrains
the orientation of the RNA in the ligation reaction such that
hybridization with it yields template for sequencing from the
5′ end of the sense strand. After hybridization, the adaptors
are ligated to the small RNA molecules using the Ligation
Enzyme Mix, which is a mixture of an RNA Ligase and
other components. Ligation requires an RNA molecule with
a 5′-monophosphate and a 3-hydroxyl end; therefore, most
small RNAs can participate in this reaction, and intact mRNA
molecules with a 5′-cap structure are excluded. Next, the
small RNA population with ligated adaptors of each sample
was reverse transcribed, to generate cDNA libraries. Treatment
with RNaseH followed, to digest the RNA from RNA/cDNA
duplexes and to reduce the concentration of un-ligated adaptors
and adaptor by-products. The cDNA libraries were amplified
using bar coded primer sets and 15–18 cycles of PCR. The
amplified cDNA libraries were cleaned up and size selected from
gel—PCR products of 105–150 bp were isolated, corresponding
to inserts derived from the small RNA population. The amplified
cDNA libraries generated were there after used for Miseq
sequencing.
miRNA pathway analysis was performed using the
microT-CDS tool available through Diana Tools 1.
Determination of AChE Activity
The acetylcholine hydrolyzing activity of AChE was measured
by the Ellman’s assay (Ellman et al., 1961) as described
1http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=mirpath/
index
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Arbel et al. (2014). Briefly, samples were diluted 1:5 with
0.2 M phosphate buffer pH 7.4. Ellman’s reagent was
added to each sample, the mixture was incubated at RT
for 20 min under darkness, acetylthiocholine iodide was
added and absorbance of the corresponding plate wells at
405 nm was monitored with Stat-Fax 2000 ELISA Reader
(Advanced Technologies, IL, USA) at 15 time points with
2 min intervals. AChE activity was calculated based on the
concentration of the resultant 5-thio-2-nitrobenzoate anion
(ε405 = 13.6 M−1 cm−1); taking into account the average
OD increment per minute and protein concentration in the
sample.
U373 Culturing, Staining and Imaging
Glioblastoma U373 cells were cultured in RPMI 1640
medium supplemented with 20 mM L-glutamine,
20 mM HEPES, penicillin-streptomycin mixture and
10% fetal calf serum. For microscopy studies, the cells
were attached onto glass slides, 3 × 104 per slide, in
complete medium for 3 h and were incubated with
biotinylated α7(179–190)-specific antibody (0.06 mg/ml)
and MitoTracker Green (Invitrogen, USA) for 100 min
at 37◦C. Cells were fixed with 4% paraformaldehyde
and treated with Streptavidin-Cychrome3 conjugate to
visualize the biotinylated antibody, followed by washes
with PBS and water, embedding in MOWIOL-DABCO and
examination in a Zeiss LSM 510 Meta confocal laser scanning
microscope.
Measuring IL-6 Produced by U373 Cells
U373 cells (3 × 105 per ml) seeded into the wells of 96-well
plates were cultured with LPS (clone 055 B5; 1 µg/ml) or
α7(179–190)-specific antibody (10 µg/ml) in the presence
or absence of the following kinase inhibitors: SB202190
(10 µM, p38 inhibitor), KN62 (1 µM, CaKMII inhibitor),
PP1 (10 µM, Src kinase inhibitor), bisindolylmaleimide
(50 nM, protein kinase C inhibitor) and Wortmaninn
(1 µM, phosphatidylinositol-3-kinase inhibitor) for 24 h.
The IL-6 concentration in the supernatants was detected
using Diaclone test system as per the manufacturer’s
instructions.
Statistical Analysis
Each experiment has been performed in minimum 7 mice and
ELISA assays for each mouse have been performed in triplicates.
The mean values for individual mice were used for statistical
analysis using Student’s t-test. The data are presented as M± SE;
∗p< 0.05; ∗∗p< 0.005.
RESULTS
Both LPS and α7(1–208)-Specific
Antibodies Modulate nAChR Composition
in the Brain
Sandwich ELISA performed with whole brain preparations
demonstrated that LPS treatment decreased the level of α7
nAChR subunits while increasing the α3 and β4 subunits.
Injections of α7(1–208)-specific antibodies additionally
decreased the α4 and β2 subunits (Figure 1A). Nicotine
(3 days) up-regulated both α7 and α4β2 nAChRs and did
not influence α3β4 ones. LPS and LPS plus α7(1–208)-
specific antibody, but not nicotine, decreased α7 and α4β2
nAChRs and non-significantly increased α3β4 ones in
mitochondria preparations (Figure 1B). LPS treatment
decreased both α7 RNA and protein in the frontal cortex,
striatum, hippocampus and cerebellum. The α7(1–208)-specific
FIGURE 1 | The level of α3, α4, α7, β2 and β4 nAChR subunits in the whole brain preparations (A) or brain mitochondria (B) of mice treated with
lipopolysaccharide (LPS), α7(1–208)-specific antibody + LPS (Abα7 + LPS) or nicotine (1 month, Nic) compared to non-treated mice (Control).
∗p < 0.05; ∗∗p < 0.005 compared to Control (n = 4).
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FIGURE 2 | Modified levels of α7 nAChR protein (A) or RNA (B) in various brain regions of mice treated with LPS, α7(1–208)-specific antibody + LPS
(Abα7 + LPS) or nicotine (Nic) compared to non-treated mice (Control). FC—frontal cortex, Str—striatum, Hip—hippocampus, Cer—cerebellum ∗p < 0.05;
∗∗p < 0.005 compared to Control (n = 8).
FIGURE 3 | Transcript levels (A) and enzyme activity (B) of acetylcholinesterase-S (AChE-S) in various brain regions of mice treated with LPS,
α7(1–208)-specific antibody + LPS or nicotine (3 days) compared to non-treated mice. Designations are similar to those in Figure 2. ∗p < 0.05; ∗∗p < 0.005
compared to Control (n = 8).
antibody did not modify the effect of LPS on α7 nAChR
RNA or protein expression. Nicotine slightly increased the
α7 protein in the striatum but did not affect its RNA level
(Figures 2A,B).
LPS and α7(1–208)-Specific Antibodies
Modulate Brain AChE Expression and
Activity
LPS exposure significantly decreased the levels of the ‘‘synaptic’’
AChE-S variant (Soreq and Seidman, 2001) in the frontal
cortex and non-significantly in the striatum, hippocampus
and cerebellum that was interpreted as a tendency to decrease.
The antibody additionally decreased AChE-S RNA in the
hippocampus. Nicotine (3 days) caused non-significant
up-regulation of AChE-S in the striatum (Figure 3A).
Enzyme activity measurements demonstrated decreased
AChE activity in the frontal cortex and cerebellum and
a tendency to decrease in the striatum and hippocampus
under the effect of LPS. The antibody accentuated the
LPS effect in the frontal cortex, while nicotine tended to
increase AChE activity in striatum (Figure 3B). A correlation
between AChE-S expression and activity was observed in
the frontal cortex, cerebellum and striatum of individual
mice (Pearson coefficient being from 0.80–0.99; data not
shown).
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FIGURE 4 | Cytochrome C release from the brain mitochondria of mice
treated with LPS or α7(1–208)-specific antibody + LPS compared to
untreated mice under the effect of Ca2+ and/or PNU282987.
Designations are similar to those in Figure 1. Shown are the normalized data
of three independent experiments, 3–4 mice in each. ∗p < 0.05; ∗∗p < 0.005
compared to Control; #p < 0.05 compared to LPS.
LPS and α7(1–208)-Specific Antibodies
Modify the Reaction of Brain Mitochondria
to Apoptotic Stimuli
Live mitochondria isolated from the brains of LPS-treated mice
released more cyt c in response to 0.9 and 9.0 µM Ca2+ and
became less sensitive to the normalizing effect of the α7-specific
agonist PNU282987 than mitochondria of non-treated animals
(Figure 4). Moreover, mitochondria of LPS-treatedmice released
some cyt c without any Ca2+, reflecting their unstable (pre-
apoptotic) state. The α7(1–208)-specific antibodies decreased the
LPS-induced cyt c release from mitochondria at low Ca2+ doses
and facilitated the normalizing effect of PNU282987.
The Effect of LPS and α7(1–208)-Specific
Antibody on the microRNA Spectrum in the
Brain
To delineate the differentially expressed miRs in brain during
inflammation we performed whole brain miR-deep sequencing
analysis. A total of 24, 249, 523 sequencing reads were obtained.
All the reads (50 bp long) were subjected to trimming of the
tag end terminal base pairs and P1 start adapter (Miseq miRNA
reverse primer sequences) using CLC genomics workbench V7.0
(CLC Inc, Aarhus, Denmark). The remaining reads (1, 88,
986) obtained were aligned against the mouse miRNA genome
(miRBase release 20) and Ensemble mouse database (GRCm38)
for non coding RNA. Through the annotation and merge counts,
only reads longer than 15 bases were analyzed. Match parameters
included for mature length variants (IsomiRs)-additional two
upstream and downstream bases, and two missing upstream and
downstream bases, andmaximum allowedmismatches two using
standard specific alignment protocol. On average, 70% (range
76.6–50.6%) of the sequences of all annotated reads were mapped
and 85% (range 90.4–76.7%) of miRBase genes were detected.
Of the mapped reads, on average 11% (range 12.2–10.8%) had
perfect match to the aligned genes, 54% (range 54.5–55.2%)-
one mismatch, 23% and (range 21.7–24.7%) two mismatches.
Mapping to Ensemble mouse database (GRCm38) yielded
mapping to 10.5% (10–11%) of all annotated database sequences
on average across libraries. Preference was given to miRBase,
so the database which was not mapped to miRBase is mapped
to this. Of them, 55.6% (range 55.6–37.3%) exhibited perfect
match to the reference sequences, 39.6% (range 39.6–51.5%)
with one mismatch, and 8.3 (8.3–11.2%) two mismatches.
These alignments yielded an average of 2.06% aligned reads of
the total number of reads (with a minimum of 0.2% and a
maximum of 3.16%). Annotated samples were grouped by both
precursor andmature sequence identity. Overall, a top 44 mature
miRs that exhibited count of at least 30 per million reads in
at least one sample were analyzed for differential expression
between the different experimental conditions. For fold change
analysis the above identified miRs of different groups were
normalized to control group and that were 1.5 up-regulated or
0.5 fold down-regulated were identified as uniquely regulated
miRs.
The wide screening of the brain RNA for the expression of
44 miRs demonstrated that the cluster of the highest expression
contained miRs-99a, let7g and 9, that the cluster of medium
expression included miRs-26a and let-7f, and that other miRs
were of quite low or very low expression. The miR-21 and
miR-434 were observed twofold up-regulated and let-7a-1 0.5
fold down-regulated. As shown in Figure 5A, all types of
treatment (LPS, LPS + α7(1–208)-specific antibody or nicotine)
influenced the level of many of them. MiR-99a was obviously up-
regulated by both nicotine and LPS and the effect of LPS was
withdrawn by the antibody. In contrast, miR-let7g was down-
regulated by LPS and, less, nicotine but the effect of LPS was
again withdrawn by the antibody. MiR-9 was up-regulated by
nicotine and much less affected by the LPS; however, again, the
antibody effect was opposite to that of LPS. MiRs-26a and let-7f
were down-regulated in all groups of treated mice; the antibody
obviously aggravated the LPS effect for miR-26a. Among other
miRs, of considerable interest are miR-21a and miR-434: both
of them were up-regulated in all treated mice, mostly by LPS,
and the antibody prevented this effect more or less efficiently.
In whole, the antibody obviously attenuated the LPS effect in 16
miRs tested and aggravated its effect in six miRs. The effects of
nicotine and LPS were of similar direction for six miRs (miR-26,
let-7f, let-7c, miR-30, miR-21a and miR-434) and showed an
opposite impact for other four miRs (miR-9, let-7j, miR-218 and
miR-125).
After miRNA differential expression analysis, we performed
KEGG pathways analysis of differentially regulated miRNA
of each group exposed to either LPS or LPS and Ab α7 or
nicotine (Figure 5B). After removing redundant terms, our
findings pointed that all pathways involved in LPS exposure
were included in LPS and Ab α7 exposure group. In addition,
this group was also associated with Notch signaling, apoptosis,
mRNA surveillance, bacterial invasion and calcium signaling
pathways. Similarly, nicotine group included all pathways
involved in LPS inflammation; in addition it was associated
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FIGURE 5 | (A) Fold changes in the levels of 44 differentially expressed miRs in the whole brain preparations of mice treated with LPS, α7(1–208)-specific antibody
+ LPS or nicotine (1 month) compared to untreated mice (Control), (B) KEGG pathway analysis of predicted signaling pathways involved.
with addiction pathways like Cocaine, Amphetamine, Retrograde
endocannabinoid signaling, apoptosis and Notch signaling.
Common KEGG pathways found in all treatment groups are
either neuronal or inflammatory pathways which included
axon guidance, MAPK signaling pathway, PI3K-Akt signaling
pathway, T cell receptor signaling pathway, Neurotrophin
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FIGURE 6 | Transcript levels of miR-132 (A) and miR-212 (B) in various brain regions of mice treated with LPS, α7(1–208)-specific antibody + LPS or
nicotine (3 days) compared to untreated mice. Designations are similar to those in Figures 1– 5. N = 5–8/group. ∗p < 0.05; ∗∗p < 0.005 compared to Control.
signaling pathway, mTOR signaling pathway, TGF-beta signaling
pathway, Wnt signaling pathway, Fc gamma R-mediated
phagocytosis, Adherence junction, Glutamatergic synapse, Long-
term potentiation, Dopaminergic synapse, Amyotrophic lateral
sclerosis (ALS), Fc epsilon RI signaling pathway, Dorso-
ventral axis formation, Cholinergic synapse, B cell receptor
signaling pathway, Jak-STAT signaling pathway, Toll-like
receptor signaling pathway, chemokine signaling pathway.
qRT PCR Analysis of miRNA-132/212 in
Different Regions of the Brain
To further understand the down-regulation in expression of
the cholinergic α7 nAChR (global) and AChE-S (brain region
specific) genes, we performed qRT PCR analysis for quantifying
the expression of AChE-S targeting miRs: miR-132 and its
co-clustered miR-212 in the above mentioned four brain regions.
We observed significant LPS-induced increases in the expression
levels of miR-212 in all of the tested brain regions, whereas
miR-132 showed region-specific (frontal cortex and cerebellum)
increases in its expression, correlating to AChE-S expression
(Figures 3A,B vs. Figure 6). The antibody tended to cause
decreases in miR-132 expression that was up-regulated by LPS
in the frontal cortex, hippocampus and striatum. In comparison,
the antibody treatment clearly prevented LPS-induced miR-212
up-regulation in all brain regions except cerebellum (Figure 6B).
Nicotine (3 days) failed to significantly affect either miR-132 or
miR-212 expression.
LPS and α7(1–208)-Specific Antibodies
Stimulate IL-6 Production by U373 Cells
through a Similar Signaling Pathway
Previously we demonstrated that α7(1–208)-specific antibodies
and even more, α7(179–190)-specific antibodies stimulated
IL-6 production in U373 cells via a p38-dependent pathway
(Kalashnyk et al., 2014). To test if similar or different
mechanisms are involved in LPS- or antibody-stimulated
IL-6 production, we tested the effect of various kinase inhibitors
on these consequences. As shown in Figure 7A, the antibody
stimulated much weaker IL-6 production compared to LPS
in U373 cells; however, both LPS-stimulated and antibody-
stimulated IL-6 levels were significantly decreased in the
presence of p38 and Src kinase inhibitors, suggesting
the involvement of a similar Src/p38-dependent signaling
pathway.
To study if internalized α7-specific antibodies can bind
mitochondria, we allowed their internalization by U373 cells
for 100 min, followed by MitoTracker Green staining. Confocal
microscopy showed no overlapping staining for the antibody and
MitoTracker (Figure 7B); therefore, the internalized antibody
seemed not to bind mitochondria.
DISCUSSION
The influence of α7 nAChR signaling on pro-inflammatory
cytokines production is well documented (de Jonge and Ulloa,
2007; Kalashnyk et al., 2014). Our data support, deepen and
extend these findings, showing that inflammation regulates
α7 nAChR and AChE-S expression and changes miRNA
profiles in the brain. Intraperitoneal LPS injections resulted in
down-regulation of brain α7 nAChR and AChE-S RNAs and
protein levels. AChE down-regulation was accompanied by up-
regulation of its targeting miRNA-132 (Shaked et al., 2009;
Shaltiel et al., 2013) in the frontal cortex and cerebellum of
LPS-treated mice. This region-specific inter-related regulation
of miRNA-132/AChE is compatible with the involvement of
the cluster harboring miRNA-132/212 in the resolution of
inflammation (Nahid et al., 2011; Rao et al., 2015). The
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FIGURE 7 | IL-6 production by U373 cells stimulated with either α7(179–190)-specific antibody or LPS in the presence or absence of various kinase
inhibitors (A) and confocal image of U373 cell with internalized α7-specific antibody (red) additionally stained with MitoTracker (green; B).
SB—SB202190 (p38 inhibitor), KN—KN62 (CaKMII inhibitor), PP—PP1 (Src kinase inhibitor), bis—bisindolylmaleimide (protein kinase C inhibitor),
Wortm—Wortmaninn (phosphatidylinositol-3-kinase inhibitor). ∗∗p < 0.005; ∗∗∗p < 0.0005 compared to the effect of LPS or α7-specific antibody alone.
general up-regulation of miRNA-212 in all studied brain
areas and its significant inhibition by the α7-specific antibody
in the frontal cortex, striatum and hippocampus suggests
its specific involvement in inflammation-related mechanisms,
different from those regulated by miRNA-132. In general,
this data indicates that the LPS-induced inflammatory reaction
also stimulated the anti-inflammatory cholinergic pathway by
leading to consequent increases in ACh levels due to down-
regulated AChE expression and activity. However, inhibiting
the expression of α7 nAChRs (which presumably mediate the
anti-inflammatory effect of ACh) makes inefficient this LPS-
stimulated anti-inflammatory response.
Down-regulation of α7 nAChRs was accompanied by the
increase of α3β4 nAChRs, similarly to what we observed in
α7−/− mice or in mice chronically treated with LPS (Lykhmus
et al., 2011, 2015). This means that α7 to α3β4 nAChRs
substitution is an established mechanism, which could possibly
be due to the chromosomal arrangement of nAChR subunit
genes; and that a rather short LPS influence (3 days) is sufficient
to stimulate this gene expression exchange. The antibody
additionally decreased α4 and β2 protein in the brain, possibly
due to the cross-reactivity of α7(1–208)-specific antibodies
with the homologous α4 subunit, resulting in α4β2 receptors
internalization and degradation. Nicotine treatment did not
cause significant changes in the nAChR or AChE expression but
up-regulated α4, α7 and β2 proteins in the whole brain that is in
accordance with the suggested chaperon-like activity of nicotine
(Sallette et al., 2005). We conclude that LPS and α7(1–208)-
specific antibodies manipulate the molecular components of the
brain’s cholinergic anti-inflammatory pathway.
Similarly to the chronic LPS treatment (Lykhmus et al., 2015),
short-term LPS exposure decreased the level of mitochondrial
α7 nAChRs and made the brain mitochondria more sensitive
to Ca2+. The α7-specific antibody prevented the additional
cyt c release from mitochondria and, therefore, supported their
resistance to apoptogenic influence. Since α7(1–208)-specific
antibodies attenuated Ca2+-stimulated cyt c release from isolated
mitochondria (Gergalova et al., 2014), we hypothesized that
the antibody could penetrate the brain cells to directly affect
mitochondria, as it was recently suggested for anti-mitochondrial
antibodies in patients with Pemfigus vulgaris (Chernyavsky
et al., 2015). However, in our experiments, no binding of
internalized antibody with mitochondria was observed in U373
cells (Figure 7B) assuming the involvement of indirect molecular
mechanism, possibly, including miRNAs.
Over a decade many miRNAs showed functional involvement
in neuro-inflammatory mechanisms (Soreq and Wolf, 2011;
Maharshak et al., 2013; Nadorp and Soreq, 2015). Analysis
of the present data suggests the involvement of miRNAs in
regulating the brain cell survival under the effect of LPS and
α7-specific antibodies. The brain-abundant miRNA-9, which
was down-regulated by LPS exposure, inhibits the expression
of a proapoptotic Bcl-2L11 found in the outer mitochondrial
membrane (Li et al., 2014); its potential pro-apoptotic effect
was largely avoided by the antibody. Another brain-abundant
miRNA-99 regulates pro-survival Akt/mTOR signaling (Jin
et al., 2013); its up-regulation with LPS was expected to
decrease the brain cell viability; whereas the α7(1–208)-specific
antibody limited this effect. Likewise, let-7g suppresses the
expression of the anti-apoptotic protein Bcl-xL (Wu et al., 2015);
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therefore, its down-regulation by LPS might be pro-apoptotic,
whereas the antibody treatment inhibited this effect. In whole,
LPS exerted anti-survival changes in multiple brain miRNAs,
and the α7-specific antibody could antagonize part of them,
providing a tentative explanation for the protective antibody
effect in mitochondria found here. According to our previously
published data, α7 nAChR is located in the outer mitochondria
membrane and its activation stimulates intramitochondrial
Pi3K/Akt signaling pathway (Gergalova et al., 2012, 2014), that
is in good agreement with the present results. The pro-survival
antibody effect also explains the data of Kamynina et al. (2013)
and Lykhmus et al. (2015), where α7-specific antibodies exerted
neuroprotection in certain models of AD.
In addition to their involvement in inflammation-related
processes, both miRNA-132 and miRNA-212 protect neurons
against H2O2-mediated cell death, and their loss causes
neuronal apoptosis via elevated levels of the cell death-
associated proteins PTEN, FOXO3 and P300 that antagonize
Akt pro-survival signaling (Wong et al., 2013). Knockdown of
miRNA-132 in the hippocampus impairs memory acquisition
(Wang et al., 2013), which can be regarded as a marker
for cognitive impairment (Xie et al., 2015). The brains of
Alzheimer patients demonstrated decreased miR-132/212 level
already at stages Braak III and IV of the disease and in a
manner related to Tau pathology (Lau et al., 2014). Regarding
our data, it may be suggested that neuro-inflammation up-
regulates miRNA-132/212 as an anti-inflammatory reaction,
which also protects the brain cells from excessive reactive oxygen
species toxicity. The α7(1–208)-specific antibodies weaken
this reaction but do not decrease miRNA-132/212 below the
control level. Obviously, the final pro- or anti-survival antibody
effect is an integral interplay of multiple miRNAs and their
targets.
The KEGG pathways analysis allowed deeper understanding
of miRNA regulating activity in the brain under the effects of
LPS, LPS and antibody or nicotine. According to the probability
of engagement, the predicted signaling pathways could be
classified into three groups (Figure 5A): extremely probable
(−log p > 20: Axon guidance, MAPK and PI3K/Akt pathways);
highly probable (20 > −log p > 10: TcR, mTOR, Wnt, TGFβ
and Neurotrophin pathways) and probable (10>−log p> 2: all
other predicted pathways).
The first group includes pathways found undermany different
receptors; therefore, it is impossible to identify any definite
one. However, comparison of −log p values found for LPS
and LPS + Ab treatments allows suggesting that the antibody
contributes additional signaling through these pathways. This is
in accord with our experimental data on the ability of α7-specific
antibody to stimulate IL-6 production in U373 cells through
p38-dependent pathway (Figure 7A). The involvement of both
MAPK and PI3K/Akt pathways in α7 nAChR signaling is well
documented (Parada et al., 2010; Yu et al., 2011; Cucina et al.,
2012; Huang et al., 2012; Cui et al., 2013). Previously we reported
that signaling of α7 nAChRs expressed in mitochondria can
be triggered by α7-specific antibody (Gergalova et al., 2014),
therefore, the antibody could engage PI3K/Akt pathway in the
brain.
The second group contains signaling pathways of TcR, TGFβ,
Wnt and Trk (neurotrophin) receptors, as well as mTOR
pathway. Again, the antibody contributes to these pathways
compared to LPS alone. The maximal increase of −log p
was observed for TcR (22 vs. 15), mTOR (17 vs. 12) and
neurotrophin (10.5 vs. 7.7) signaling pathways. Neurotrophins
acting through Trk receptors activate PI3K/Akt and MAPK
pathways, and the mTOR functions downstream of PI3K/Akt
signaling pathway in response to cytokines and growth factors
(LoPiccolo et al., 2008; Longo and Massa, 2013); therefore,
their engagement by the antibody may be explained by the
antibody effect found in group 1. Neurotrophin signaling is
strongly stimulated by nicotine (14 (Nic) vs. 7.5 (LPS) vs.
10.5 (LPS + Ab)) that also assumes the involvement of nicotinic
receptors and, possibly, their cross-talk with Trk receptors.
T lymphocytes are normally not found in the brain parenchyma
but can penetrate there under neuroinflammation when the
blood-brain barrier is disrupted (Engelhardt, 2006). In addition,
they could be found in the brain capillaries (since the brains
had not been perfused before RNA extraction). The antibodies
significantly contributed to this pathway; therefore, they could
facilitate T lymphocyte migration to or penetration into the
brain and subsequent activation resulting in TcR signaling
pathway involvement. The Wnt and TGFβ signaling pathways
are engaged by all three treatments; however, there is no
significant difference between nicotine, LPS or LPS + Ab-treated
mice.
Among other signaling pathways of interest are the Notch
and apoptosis signaling, which are found in nicotine- and LPS
+ Ab- but not LPS-treated mice and, therefore, relate to nicotinic
receptors. The Notch signaling pathway components expressed
in the brain were shown to be involved in the pathogenesis of AD
(Woo et al., 2009) and, therefore, this pathway may contribute
to thememory impairment found in α7(1–208)-immunizedmice
(Lykhmus et al., 2015). The involvement of nAChRs in regulating
cell survival and apoptosis has already been discussed. The data
of KEGG analysis predict the miRNA-mediated regulation of
apoptosis pathway by α7(1–208)-specific antibodies that is in
accord with the analysis of molecular targets of miRs 9, 99 and
let-7g described above.
LPS notably stimulates pro-inflammatory cytokines
production via toll-like receptor type 4 (TLR-4)/CD14 receptor
complex, resulting in MAP kinases activation and a nuclear
localization of NF-κB (Kawai and Akira, 2010; Nadorp and
Soreq, 2015) also engaging TLR-4 to Src activation (Liu et al.,
2012). Here, we show that similar enzymes (Src kinases and
p38) are involved in the signal transduction pathway from
either LPS or α7-specific antibodies, suggesting that the α7
nAChR can directly influence TLR-4 signaling. Together
with the parallel TLR9/ACh interaction (Nadorp and Soreq,
2015), these findings explain how ACh may attenuate the
LPS-induced pro-inflammatory cytokine production through
α7 nAChR. Inversely, α7-specific antibodies stimulate TLR-4
pro-inflammatory signaling, predicting close TLR-4 and α7
nAChR proximity in the plasma membrane. Although LPS
failed to prevent binding of the α7-specific antibodies to U373
cells in flow cytometry (data not shown), one might predict an
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FIGURE 8 | Schematic diagram demonstrating the effects of LPS and α7(1–208)-specific antibodies (α7Ab) in the brain. LPS down-regulates AChR
expression resulting in acetylcholine increase, down-regulates α7 nAChR expression and changes the levels of miR-132/212, miR-9, miR-99 and let-7g. The α7Ab
further decrease AChE and α7 nAChRs but antagonize LPS effects on miRNAs. As a result, the α7Ab aggravates the LPS-induced inflammation but may support the
brain cell viability.
intersection of α7 nAChR signaling with TLR-4 at the level of
adaptor proteins or Src-kinases, i.e., at the very upstream, plasma
membrane-proximal stage.
Taken together, our current findings, summarized in
Figure 8, demonstrate that:
1. LPS-induced inflammation stimulates the ACh-mediated and
miRNA-regulated anti-inflammatory pathway in the brain;
however, down-regulation of the α7 nAChRs makes this
pathway ineffective;
2. Inflammation dampens the mitochondrial cholinergic anti-
apoptotic pathway and stimulates miRNAs assumed to
decrease the brain cells viability;
3. The α7-specific antibody aggravates LPS-induced
inflammation by preventing the expression of anti-
inflammatory miR-212 and stimulates the LPS-like signaling
by itself;
4. The α7-specific antibody dampens the excessive up-regulation
of pro-apoptotic miRNAs upon inflammation and maintains
mitochondrial integrity that may support the brain cells
viability.
This data support the idea that excessive inflammation is
an important pathogenic factor stimulating neurodegenerative
processes. In this context, α7 nAChR-specific antibodies may
play a dual role: potentiating a certain level of inflammation but
preventing its neurodegenerative consequences.
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